Published • loading... • Updated
Billionaire Mehta Brothers’ Torrent To Buy Stake In India’s JB Pharma In $1.4 Billion Deal
INDIA, JUN 29 – The Rs 25,689 crore deal will expand Torrent's portfolio into chronic diseases and ophthalmology and includes a mandatory open offer for 26% of JB Chemicals shares, the second-largest pharma acquisition in India.
- On June 29, 2025, Torrent Pharmaceuticals entered into definitive agreements to purchase a controlling interest in JB Chemicals & Pharmaceuticals in India, with the deal valued at ₹25,689 crore .
- The acquisition follows KKR's decision to sell its 46.39% stake via Tau Investment Holdings, with Torrent purchasing 26% more through a mandatory open offer and an additional 2.8% from employees.
- The deal will be executed in two phases, culminating in a merger where every 100 JB Pharma shares convert to 51 Torrent shares, subject to regulatory approvals from Indian authorities.
- Torrent Executive Chairman Samir Mehta expressed satisfaction with integrating JB Pharma’s legacy into Torrent’s operations, emphasizing this move as a foundation for the company’s future growth and strategic development.
- The acquisition diversifies Torrent’s platform with JB Pharma’s fast-growing Indian business and CDMO capabilities, aiming to strengthen market share and scale revenue and profitability in India and globally.
Insights by Ground AI
31 Articles
31 Articles
Torrent to Acquire KKR’s Stake in JB Pharma for $1.4 Billion
·New York, United States
Read Full Article
Torrent seals deal to buy JB Chemicals
Torrent Pharma to acquire 46.39% stake in JB Chemicals from KKR for Rs 11,917 crore, valuing the company at Rs 25,689 crore. Deal includes open offer, merger plan, and aims to boost Torrent’s domestic and global footprint, with strong chronic care and CDMO synergies. Regulatory nods awaited.
·Noida, India
Read Full ArticleCoverage Details
Total News Sources31
Leaning Left1Leaning Right6Center7Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
C 50%
R 43%
Factuality
To view factuality data please Upgrade to Premium
